Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: ‘exposing the invisible’

Simple item page
dc.citation.epage746en_US
dc.citation.issueNumber5en_US
dc.citation.spage741en_US
dc.citation.volumeNumber19en_US
dc.contributor.authorOkutucu, S.en_US
dc.contributor.authorKatircioglu-Öztürk, D.en_US
dc.contributor.authorOto, E.en_US
dc.contributor.authorGüvenir, H. A.en_US
dc.contributor.authorKaraagaoglu, E.en_US
dc.contributor.authorOto, A.en_US
dc.contributor.authorMeinertz, T.en_US
dc.contributor.authorGoette, A.en_US
dc.date.accessioned2018-04-12T11:04:30Z
dc.date.available2018-04-12T11:04:30Z
dc.date.issued2016en_US
dc.departmentCyberparken_US
dc.departmentDepartment of Computer Engineeringen_US
dc.description.abstractAims: The aims of this study include (i) pursuing data-mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial dataset containing atrial fibrillation (AF) burden scores of patients with many clinical parameters and (ii) revealing possible correlations between the estimated risk factors of AF and other clinical findings or measurements provided in the dataset. Methods: Ranking Instances by Maximizing the Area under a Receiver Operating Characteristics (ROC) Curve (RIMARC) is used to determine the predictive weights (Pw) of baseline variables on the primary endpoint. Chi-square automatic interaction detector algorithm is performed for comparing the results of RIMARC. The primary endpoint of the ANTIPAF-AFNET 2 trial was the percentage of days with documented episodes of paroxysmal AF or with suspected persistent AF. Results: By means of the RIMARC analysis algorithm, baseline SF-12 mental component score (Pw = 0.3597), age (Pw = 0.2865), blood urea nitrogen (BUN) (Pw = 0.2719), systolic blood pressure (Pw = 0.2240), and creatinine level (Pw = 0.1570) of the patients were found to be predictors of AF burden. Atrial fibrillation burden increases as baseline SF-12 mental component score gets lower; systolic blood pressure, BUN and creatinine levels become higher; and the patient gets older. The AF burden increased significantly at age >76. Conclusions: With the ANTIPAF-AFNET 2 dataset, the present data-mining analyses suggest that a baseline SF-12 mental component score, age, systolic blood pressure, BUN, and creatinine level of the patients are predictors of AF burden. Additional studies are necessary to understand the distinct kidney-specific pathophysiological pathways that contribute to AF burden. Published on behalf of the European Society of Cardiology.en_US
dc.description.provenanceMade available in DSpace on 2018-04-12T11:04:30Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 179475 bytes, checksum: ea0bedeb05ac9ccfb983c327e155f0c2 (MD5) Previous issue date: 2017en
dc.identifier.doi10.1093/europace/euw084en_US
dc.identifier.eissn1532-2092
dc.identifier.issn1099-5129
dc.identifier.urihttp://hdl.handle.net/11693/37158
dc.language.isoEnglishen_US
dc.publisherOxford University Pressen_US
dc.relation.isversionofhttp://dx.doi.org/10.1093/europace/euw084en_US
dc.source.titleEP Europaceen_US
dc.subjectAtrial fibrillationen_US
dc.subjectBlood urea nitrogenen_US
dc.subjectCreatinineen_US
dc.subjectData miningen_US
dc.subjectMachine learningen_US
dc.subjectRIMARCen_US
dc.subjectSF-12en_US
dc.subjectAngiotensin II antagonisten_US
dc.subjectCreatinineen_US
dc.subjectNitrogenen_US
dc.subjectUreaen_US
dc.subjectAngiotensin receptor antagonisten_US
dc.subjectAntiarrhythmic agenten_US
dc.subjectAntihypertensive agenten_US
dc.subjectImidazole derivativeen_US
dc.subjectOlmesartanen_US
dc.subjectTetrazole derivativeen_US
dc.subjectAccuracyen_US
dc.subjectAgeen_US
dc.subjectAlgorithmen_US
dc.subjectArticleen_US
dc.subjectAtrial fibrillationen_US
dc.subjectControlled studyen_US
dc.subjectFemaleen_US
dc.subjectHumanen_US
dc.subjectMaleen_US
dc.subjectMeasurementen_US
dc.subjectMulticenter studyen_US
dc.subjectParoxysmal atrial fibrillationen_US
dc.subjectPriority journalen_US
dc.subjectProspective studyen_US
dc.subjectRandomized controlled trialen_US
dc.subjectRisk factoren_US
dc.subjectShort form 12en_US
dc.subjectSystolic blood pressureen_US
dc.subjectUrea nitrogen blood levelen_US
dc.subjectWeighten_US
dc.subjectAge distributionen_US
dc.subjectAgeden_US
dc.subjectAtrial fibrillationen_US
dc.subjectComorbidityen_US
dc.subjectData miningen_US
dc.subjectDouble blind procedureen_US
dc.subjectHypertensionen_US
dc.subjectIncidenceen_US
dc.subjectMiddle ageden_US
dc.subjectPrevalenceen_US
dc.subjectProceduresen_US
dc.subjectSex ratioen_US
dc.subjectTreatment outcomeen_US
dc.subjectVery elderlyen_US
dc.subjectAge Distributionen_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAngiotensin receptor antagonistsen_US
dc.subjectAnti-Arrhythmia agentsen_US
dc.subjectAntihypertensive agentsen_US
dc.subjectAtrial fibrillationen_US
dc.subjectComorbidityen_US
dc.subjectData miningen_US
dc.subjectDouble-Blind methoden_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectHypertensionen_US
dc.subjectImidazolesen_US
dc.subjectIncidenceen_US
dc.subjectMaleen_US
dc.subjectMiddle ageden_US
dc.subjectPrevalenceen_US
dc.subjectRisk factorsen_US
dc.subjectSex distributionen_US
dc.subjectTetrazolesen_US
dc.subjectTreatment outcomeen_US
dc.subjectTurkeyen_US
dc.titleData mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: ‘exposing the invisible’en_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial ‘exposing the invisible’.pdf
Size:
192.67 KB
Format:
Adobe Portable Document Format
Description:
Full printable version
Download

Collections

Scholarly Publications - Computer Engineering